ADMA Biologics price target raised to $13 from $10 at H.C. Wainwright

H.C. Wainwright analyst Raghuram raised his price target for ADMA Biologics to $13 from $10 following FDA approval of RI-002. Further, the analyst continues to expect near-term feedback from the FDA on ADMA’s response to the Complete Response Letter for Bivigam that the FDA issued in late December 2018. The approval of RI-002 should have favorable implications for the approval of the Bivigam, says the analyst. He reiterates a Buy rating on ADMA Biologics.
https://thefly.com/landingPageNews.php?id=2892395